🚨
@HFSA
HF Stats - Epidemiology & Outcomes🚨
**LIVE @ JCF**
Your one-stop-shop for HF data
💠Check it out here:
💠Summary slideset below in 🧵
💠HFSA site:
@robmentz
@dranulala
We are pleased to announce that Robert J. Mentz, MD has been named our new Editor-in-Chief.
@robmentz
will begin his term on Dec. 1. Welcome aboard, Dr. Mentz! Read the full press release >>
@HFSA
🚨Assess and consider implications of the RA in HFpEF - New Paper investigating the Impact of Right Atrial Remodeling in Heart Failure With Preserved Ejection Fraction - Out Now in JCF!
@HFSA
Many pts w HFpEF are on a beta-blocker. Latest science out of SwedeHF Registry Explores this further:
"Association Between β-Blockers & Outcomes in HFpEF: Current Insights From the SwedeHF Registry"
👉
@robmentz
@dranulala
@HFSA
What happens to PVR after LVAD? Significant ⬇️ early. But 1 in 4 ➡️ persistent high PVR, especially when severe mitral regurgitation remains. Fresh press
@JCardFail
and
#TakeHomeVisual
@HFSA
New in
@JCardFail
: In this thoughtful & important article,
@ZekunFengMD
,
@gcfmd
,
@boback
show that Pall Care Services are underutilized in cardiogenic shock admissions. PCS associated with lower 30d readmission and lower cost.
@AshishCorrea
Engaging JCF Editorial Board Member meeting at
#HFSA2021
- great dialogue & discussion of exciting next steps and new initiatives! Incredible to see our multi-disciplinary team all together (some via zoom).
@HFSA
[quick mask down for photo]
@robmentz
@dranulala
@amorrismd
@vbluml
The use of pulmonary artery catheter in
#CardiogenicShock
has decreased from 2004-2014, although its use is now associated with improved outcomes, which may reflect better selection of patients or better use of the information to guide therapies.
@HFSA
PAPi = (PA systolic - PA diastolic) / RA In ambulatory patients with symptomatic HF who were not planned for advanced therapies, PAPi outperformed other hemodynamic measures to predict death or hospitalization at 6 months.
#VisualAbstract
🚨Pregnancy & OHT: Summary of current evidence & recs for preconception counseling, medical management and surveillance, maternal outcomes, breastfeeding. Emphasis on multidisciplinary cardio-ob team❤️
@MKIttlesonMD
@ersied727
@JCardFail
@HFSA
#HFWeek2021
"Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for HF"
💠
#TRANSLATEHF
data from
#GWTGHF
: benefits of starting
#SGLT2i
during hospitalization for HF among Medicare beneficiaries
@AHAScience
👉
New
@JCardFail
: Dynamic maneuvers have heterogenous effects on LVAD flows depending on loading conditions & compensatory responses. Assessment of the effects may help individualize care – see algorithm from authors!
@AshishCorrea
#TakeHomeVisual
Frailty is common in older adults with multiple medical conditions. SPPB tests leg function to measure frailty. 75% of outpatients with HFpEF were at least mildly frail by the SPPB, which also independently predicted poor outcomes in this population.
JCF April Editor's Page
#WordsMatter
Continued: Moving from “Candidacy” To “Benefit Derived”
EX: “Mr. X is not a candidate for transplantation"➡️
"Mr. X is unlikely to benefit from heart transplantation at this time due to..."
@robmentz
@dranulala
👉🏾
What's the role for ARNI in HF w EF>40% following a WHF event?
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial:
Sac/Val versus Val in HFmrEF and HFpEF with a Worsening Heart Failure Event
@robmentz
@ShelleyZieroth
@KSharmaMD
What is the parallel impact of CRT on reverse remodeling, VO2, and mitochondrial function? Check out this research letter
@JCF
led by
@PieterMartensMD
and colleagues.
ICYMI:
🤔Does the duration of heart failure influence the impact of ARNI initiation in pts w/ chronic HFpEF?
👇 post hoc sub-analysis of PARAGON-HF sought to answer that very ❓❓❓
🧵1/6
🔥JCF Ignite!🔥
Enhancing impactful discourse
"Do the Favorable Effects of Digoxin & SGLT2 Inhibitors Really Differ in Patients with HFrEF?
A Provocative Side-by-Side Examination of Trial Outcomes"
By Milton Packer &
@FaiezZANNAD
OPEN ACCESS 👇
🔥Out now in
#JCF
! This brief report shows that in the ongoing FINEARTS-HF trial, incorporating UACR reclassified kidney risk in 1/3 trial pts and US adults with HF, emphasizing the importance of albuminuria as part of comprehensive risk assessment.
🔗
This scientific statement on
#diabetes
and
#heartfailure
summarizes epi, pathophys, and impact on outcomes; reviews approach to pharmacological therapy; highlights value of multidisciplinary interventions; and outlines priorities for future research.
🚨Now in JCF: "Making the Case for an Expanded Indication for Sac/Val in HF" - Drs. Solomon & McMurray describe the rationale presented to the FDA for the expanded indication. Check this out - FREE to ALL:
@HFSA
@scottdsolomon
@UoGHeartFailure
Whether you're working to improve the HF clinic or launching it for the 1st time - here's a thoughtful roadmap:
"Building a HF Clinic: A Practical Guide from the
@HFSA
"
@SJGreene_md
@JavedButler1
-HFSA Quality of Care Committee
@robmentz
@dranulala